

### Reagents to Produce Purified Human 14–3–3 Zeta and 14–3–3 Epsilon as Glutathione-S-Transferase Fusion Protein

David Klein, Surajit Ganguly (NICHD), DHHS Reference No. E-142–2002—Research Material.

*Licensing Contact:* Peter Soukas; 301/435–4646; *soukasp@mail.nih.gov*.

14–3–3 proteins are thought to be involved in some way in prion-based diseases, including Bovine Spongiform Encephalopathy (BSE). The preparations described in this invention can be used to make large amounts of two human forms of 14–3–3 proteins, zeta and epsilon. These proteins can be used to raise antisera against human 14–3–3 proteins and in assays of proteins that bind 14–3–3 proteins to monitor prion-caused diseases. Additionally, the 14–3–3 proteins described in this invention may be used as vaccines to immunize against proteins involved in prion diseases.

The materials described in this invention are available nonexclusively through a biological materials license. The materials are further described in Ganguly S. *et al.*, “Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14–3–3-binding switch in melatonin synthesis,” *Proc. Natl. Acad. Sci. U.S.A.* 2001 Jul 3;98(14):8083–8 and Obsil T. *et al.*, “Crystal structure of the 14–3–3zeta:serotonin N-acetyltransferase complex. a role for scaffolding in enzyme regulation,” *Cell*. 2001 Apr 20;105(2):257–67.

Dated: April 18, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04–9465 Filed 4–23–04; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Eye Institute Special Emphasis Panel, Loan Repayment Program.

*Date:* April 29, 2004.

*Time:* 12 PM to 1:30 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Houmam H Araj, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, NIH, 5635 Fishers Lane, Suite 1300, Bethesda, MD 20892–9602, (301) 451–2020, *haraj@mail.nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: April 20, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–9458 Filed 4–23–04; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Health, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel, RFA-Research Scientist Award for Minority Institutions—(Not-HL–03–015).

*Date:* May 20, 2004.

*Time:* 7 p.m. to 10 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Chitra Krishnamurti, PhD., Review Branch, Room 7206, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0303.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel, RFA-HL–04–002, Partnership Programs to Reduce Cardiovascular Disparities.

*Date:* May 21, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Chitra Krishnamurti, PhD., Review Branch, Room 7206, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0303.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233., National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: April 20, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–9454 Filed 4–23–04; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Child Health and Human Development; Notice of Closed Meeting.

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel, Subplate Neurons in Survivors of Prematurity.

*Date:* April 29, 2004.

*Time:* 3 p.m. to 4:30 p.m.